Q4 2025 EPS Estimates for Surmodics, Inc. Raised by Zacks Research (NASDAQ:SRDX)

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Analysts at Zacks Research raised their Q4 2025 EPS estimates for Surmodics in a note issued to investors on Tuesday, April 9th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.66 per share for the quarter, up from their previous estimate of $0.64. The consensus estimate for Surmodics' current full-year earnings is ($0.90) per share.

Several other research analysts have also recently issued reports on the stock. StockNews.com raised shares of Surmodics from a "hold" rating to a "buy" rating in a report on Thursday, December 14th. Needham & Company LLC reissued a "buy" rating and set a $47.00 target price on shares of Surmodics in a report on Wednesday.

Surmodics Stock Performance

Shares of NASDAQ:SRDX traded down $0.11 on Wednesday, hitting $27.64. 53,666 shares of the company were exchanged, compared to its average volume of 45,497. Surmodics has a 1-year low of $16.79 and a 1-year high of $39.41. The stock's 50 day moving average price is $30.10 and its 200 day moving average price is $32.09. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $393.59 million, a P/E ratio of 72.74 and a beta of 1.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRDX. Kennedy Capital Management LLC increased its holdings in Surmodics by 227.7% in the second quarter. Kennedy Capital Management LLC now owns 293,359 shares of the company's stock valued at $9,185,000 after buying an additional 203,832 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Surmodics during the first quarter worth about $4,585,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Surmodics during the first quarter worth about $2,650,000. Jane Street Group LLC purchased a new stake in shares of Surmodics during the first quarter worth about $2,059,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Surmodics during the first quarter worth about $1,763,000. Hedge funds and other institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).